Dalvance J Code: HCPCS J0875 Billing Guide

The topic of this guide identifies HCPCS J0875 as the code associated with Dalvance billing. Practices should validate the current code description, unit conventions, payer requirements, and claim configuration against authoritative coding resources and their payer-specific policies before submission. The code alone does not resolve questions about authorization, benefit classification, administration billing, documentation, or reimbursement.

Review the complete workflow rather than focusing only on the drug code. Confirm that the therapy is documented, the claim reflects the administered service, units and NDC information are consistent, related administration charges are captured, and eligibility or authorization requirements were addressed. Then compare claim outcomes with payer terms and investigate rejections, denials, short-pays, and unresolved balances.

Authorization requirements vary by payer, plan, benefit classification, site of care, and the circumstances of treatment. A practice should verify eligibility and benefits, determine whether the therapy is handled under the medical or pharmacy benefit, and document any authorization request and response. Do not assume that approval for the drug automatically covers administration or every related service.

The applicable benefit can depend on the payer, plan, dispensing pathway, and treatment setting. Infectious disease practices should verify the benefit before therapy, document the payer’s instructions, and confirm whether separate requirements apply to the drug, administration, and related professional services. Confusion between medical and pharmacy benefits can contribute to rejected claims, delayed payment, or unreimbursed acquisition costs.

Supporting documentation should accurately connect the clinical indication, treatment decision, administered therapy, dosage or units, site of care, and related services to the claim. Practices should also retain relevant authorization records, drug identifiers, administration documentation, and medical-necessity information when required by the payer. The exact documentation standard is payer-specific, so internal workflows should reflect current policy and contract requirements.

Reconcile payments against the applicable payer terms for the drug, administration, and related evaluation and management services. Compare the submitted claim, adjudication detail, units, NDC information, fee schedule treatment, and contractual allowance. This review can reveal short-pays, incorrect fee schedule application, mismatches, or unpaid claim components. Findings should be tracked through dispute or appeal resolution.

Common root causes can include missing or incorrect authorization, medical-versus-pharmacy benefit confusion, drug or administration coding problems, unit or NDC mismatches, incomplete documentation, and claim-submission errors. Categorizing denials by cause helps a practice distinguish isolated corrections from workflow problems. The results can then be shared with clinical, coding, authorization, and front-office teams to reduce recurrence.

A general guide cannot determine a practice’s exact reimbursement, acquisition cost, or margin. Those figures depend on payer contracts, plan rules, purchasing arrangements, claim details, and practice-specific operating costs. GrowInfectiousDisease’s approach is to help practices apply their own verified numbers, review the full revenue cycle, and identify where revenue may be delayed, denied, underpaid, or left uncollected.